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Abstract 
Chemotherapy-Induced Peripheral Neuropathy Education and Assessment 
Kim Schmidt 
2015 
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of most 
chemotherapeutic agents used to treat cancer. To ensure the best possible care and 
outcomes for patients, nurses should be at the forefront of CIPN education and patient 
assessments. The purpose of this project was to evaluate an educational intervention for 
oncology nurses on CIPN and CIPN patient assessment by assessing the knowledge and 
confidence level of nurses in assessing CIPN before and after an educational session. The 
methodology for this project was a quasi-experimental one-group pretest multiple posttest 
design with a convenience sample of nurses employed by the Cancer Center. 
Questionnaires with Likert scale measurements for nurses’ confidence and multiple 
choice questions for nurses’ knowledge were used to gather data. The mean confidence 
level increased from pretest to both posttests, and statistical significance was reached in 
the increase in overall confidence. The nurses showed increased knowledge with 
statistical significance reached. Further inquiry is suggested with a larger sample size and 
a confidence and knowledge test that has been tested for validity. 
Keywords: Chemotherapy-induced peripheral neuropathy, neuropathy, nursing 
education, nursing knowledge, nursing confidence, oncology nurses, infusion nurses, 
cancer, oncology, professional development, nurse continuing education, nurse 
assessment.   
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Chapter I: Introduction and Background 
Introduction 
 Peripheral neuropathy (PN) occurs because of damage or dysfunction of 
peripheral nerves, which can impair motor, sensory, and autonomic function 
(Stubblefield et al., 2009). These impairments can lead to decreased quality of life (QoL), 
decreased ability to manage activities of daily living, decreased physical abilities, and 
possibly decreased life expectancy (Stubblefield et al., 2009). Many chemotherapeutic 
agents given to treat cancer can cause PN and most cancer types are treated with 
neurotoxic chemotherapy (Hershman et al., 2014; Stubblefield et al., 2009). 
Understanding PN and its early detection are imperative for effective management of 
chemotherapy-induced peripheral neuropathy (CIPN) (Stubblefield et al., 2009).  
Because CIPN is a devastating side effect of many chemotherapy agents, it is 
essential for nurses to know how to assess for this complication. Historically, CIPN has 
been more commonly discussed with patients because of voluntary reporting and not 
clinician query (Stubblefield et al., 2009). Oncology nurses often have a unique 
relationship with their patients because of the length of time spent with the patients from 
the time of diagnosis, throughout treatment, and follow up. This gives nurses the 
opportunity to build a relationship and work closely with patients and conduct thorough 
assessments. Oncology nurses believe assessments for CIPN are necessary, but lack the 
confidence to perform them (Binner, Ross & Browner, 2011). More education is needed 
to enable oncology nurses in performing routine assessments for CIPN in patients 
receiving neurotoxic chemotherapies.  
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Significance of the Problem 
 According to the American Cancer Society (2014), there are nearly 14.5 million 
cancer survivors in the United States, and this number continues to grow as the aging 
population grows.  For cancer patients treated with multiple agents, the incidence of 
CIPN is approximately 38% (Hershman et al., 2014). Some patients will return to 
baseline; however, some patients are never able to improve. Currently, there is no cure 
for CIPN. Treatment is primarily focused on pain management. Chemotherapy may be 
manipulated through treatment delays or dose reduction to ameliorate CIPN in certain 
cases (Stubblefield et al., 2009). 
The National Comprehensive Cancer Network (NCCN) guidelines recommend 
baseline assessment and continued assessment during treatment, which should include 
patient grading assessment, pain assessment, and functional assessment (Stubblefield et 
al., 2009). Treatment and referral must be prescribed by the providers, but nurses can 
play an integral role in assessing and identifying patients with CIPN. Binner et al. (2011) 
found that 75% of nurses studied believed their CIPN assessment skills were fair to poor 
and they lacked confidence in their assessment skills. With proper education, nurses 
should be appropriately prepared to administer the assessments necessary for CIPN 
which may increase the identification of and improve outcomes for patients with CIPN. 
Despite no cure or preventive treatment for CIPN, identification by nurses may benefit 
the patient through better symptom management and informed decision-making. Patients 
are more satisfied with treatment decisions when they feel well-informed (Martinez, 
Schwartz, Freres, Fraze, & Hornik, 2009). Early identification and intervention as able 
are extremely important; however, there is currently no gold standard for the evaluation 
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of CIPN (Stubblefield et al., 2009). The available guidelines on CIPN do not offer gold 
standard recommendations on how to educate nurses and assess patients (Hershman et al., 
2014; Stubblefield et al., 2009; Visovsky, Collins, Abbott, Aschenbrenner, & Hart, 
2007). The American Society of Clinical Oncology (ASCO) (Hershman et al., 2014) and 
Oncology Nursing Society (ONS) (Visovsky et al., 2007) guidelines focus on prevention 
and management of CIPN through pharmacologic and nonpharmacologic interventions. 
The NCCN guidelines are broader, but still do not suggest a specific protocol for 
healthcare provider education or patient assessments (Stubblefield et al., 2009).  
Additionally, the assessment and documentation of CIPN in the Cancer Center 
was insufficient. The majority of patients treated at the Cancer Center are treated with 
neurotoxic chemotherapy, thus putting them at risk for CIPN. There was no formal 
process for adequate assessment of patients for CIPN in this clinic. All patients are 
queried about their pain level at every appointment; however, a generic query of pain on 
a scale of 1-10 is not specific enough for neuropathic pain (Mann, 2008). All cancer 
patients are asked to fill out the NCCN Distress Thermometer (Appendix A) prior to each 
appointment, which includes questions regarding symptoms experienced such as pain or 
tingling in the hands or feet. Albeit useful, this tool is not all encompassing of the aspects 
needed to fully assess for CIPN, particularly for function, motor, and sensory. A nurse-
driven protocol was developed from the ONS PEP card for patients who call in to the 
Cancer Center with symptoms of CIPN (Visovsky et al., 2007). However, this protocol 
was not successfully implemented and there had been little to no education for the nurses 
on this topic. Nurses were requesting more education so they would feel more prepared to 
care for patients with CIPN. 
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Population of Interest 
 The population of interest for this project was oncology nurses in a Midwest 
outpatient Cancer Center caring for patients who have cancer and receive chemotherapy 
known to cause peripheral neuropathy. Oncology nurses are distinct because of the close 
contact they have with patients during a vulnerable period in their life. Oncology nurses 
often have a very close relationship with patients through which trust and rapport is built 
throughout cancer diagnosis, treatment, and follow ups, this allowing for open 
communication, education, and higher quality of care (Maxwell, 2013). Nurses that are 
educated about side effects and assessment techniques will ensure patients receive the 
highest quality care (Maxwell, 2013).  
Clinical Question 
 The aim of this project was to evaluate an educational intervention for oncology 
nurses on CIPN and CIPN patient assessment. The clinical question was as follows: What 
is the effect of an educational program on oncology nurses knowledge of CIPN and 
confidence in assessing patients for CIPN over a three month period of time compared to 
baseline knowledge and confidence level? The following expands on the clinical question 
of interest in PICOT format.  
P: Population of interest. The population of interest was oncology nurses at a 
Midwest outpatient Cancer Center that care for patients who receive chemotherapy 
known to cause peripheral neuropathy. 
      I: Intervention of interest. The intervention for this project was an education 
session for nurses about CIPN. An educational PowerPoint presentation with handouts 
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was presented to the nurses. Nurses were also educated on how to assess patients for 
CIPN with hands on demonstrations. 
         C: Comparison of interest. The project intended to compare nurses’ knowledge 
of CIPN and their confidence level with assessing for CIPN, at baseline, immediately 
following education, and three months after education. 
         O: Outcomes of the interest. The intended outcomes for this project were to 
increase nurses’ knowledge of CIPN and their confidence level with assessing for CIPN.  
        T: Time. The project was conducted over a 3 month period of time. 
Purpose of the Project 
 The purpose of this project was to evaluate the knowledge of nurses regarding 
CIPN and their confidence level in assessing CIPN before and after an educational 
session. Without proper education, nurses may not identify patients with or at risk for 
CIPN so they can be properly managed. Nurses who lack knowledge of CIPN and lack 
confidence in CIPN assessment may not be able to properly care for patients and give 
them the best quality care possible. Without this project, there could have been a 
continued lack of understanding of CIPN and decreased confidence level of oncology 
nurses regarding CIPN. This could have led to less than ideal care for patients, decreased 
QoL, and possibly decreased life expectancy. This project has opened the door for 
ongoing projects aimed at increasing the identification, better staging of, and better 
management of CIPN. 
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Research Questions 
 The following are the research questions this project intended to answer: 
1. What is the effect of an educational program about CIPN on oncology 
nurses’ knowledge level? 
2.  What is the effect of education and hands on demonstration on nurses’ 
confidence level in assessing for CIPN in patients? 
3. What is the effect of a three month time lapse on the knowledge and 
confidence level of nurses in regards to CIPN?  
Definitions  
Oncology nurses care for patients and families who have or had cancer. The role 
of an oncology nurse is to monitor symptoms, educate patients, and advocate for the 
patient and family. During cancer treatments, patients may be seen in the office several 
times a week, or every few weeks. The oncology nurse may be the only healthcare 
provider patients see during some of these visits. Often times cancer survivors are 
monitored for years, or even for their lifetime, through which time patients become very 
acquainted with the healthcare providers in the Cancer Center.  
Infusion nurses are nurses who administer IV medications. In the Cancer Center, 
infusion nurses administer several types of chemotherapy, biotherapy, hydration, anti-
emetics, and many more drugs in an outpatient setting. Infusion nurses are with patients 
throughout treatment, which may last from several minutes to several hours. This 
provides a unique opportunity to create a relationship with patients. 
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Cancer Center refers to the local oncology clinic where the project took place, the 
setting. The Cancer Center is an adult outpatient medical oncology center and infusion 
center where office visits are conducted and chemotherapy, other infusions, and 
injections are administered. 
Chemotherapy-induced peripheral neuropathy is a common side effect of some 
chemotherapy, known as neurotoxic chemotherapy, caused from damage or dysfunction 
of the peripheral nerves. Motor, sensory, and autonomic dysfunction can result from 
peripheral neuropathy (Stubblefield et al., 2009). Some of the signs and symptoms of 
CIPN include numbness, tingling, pain, gait disturbance, difficulty picking objects up or 
holding onto objects, diarrhea, constipation, urinary retention, impotence, and 
hypotension. Decreased QoL, disability, and possibly even shorter survival may result 
from CIPN. The exact cause of CIPN is not known. CIPN may also be referred to by the 
drug of cause- taxane induced peripheral neuropathy, or oxaliplatin induced peripheral 
neuropathy.  
Neurotoxic chemotherapies are drugs given to patients, most commonly cancer 
patients, known to cause neurologic dysfunction, such as CIPN. It is not well-known why 
neurotoxic chemotherapies damage peripheral nerves and pathogenesis may vary with the 
drug used. Neurotoxic chemotherapies may damage sensory axons, causing deterioration 
and dying back of axons and myelin sheaths (Wickham, 2007). Cumulative doses of 
neurotoxic chemotherapy seem to cause more CIPN. Common neurotoxic 
chemotherapies include taxanes, platinums, vinca alkaloids, bortezomib, and thalidomide 
(Stubblefield et al., 2009).  
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Educational program for nurses on CIPN included a one-hour class with a 
PowerPoint presentation (Appendix B) and discussion conducted by the primary project 
lead. Information included in the educational program consisted of neurological 
pathophysiology, prevalence of CIPN, signs and symptoms of CIPN, and strategies to 
manage CIPN.  Nurses were also educated through discussion and hands on 
demonstration on how to assess patients for CIPN. Handouts were given to the nurses 
covering information on how to assess patients for CIPN. The setting for the educational 
program was the Cancer Center break room as there was audiovisual equipment, 
adequate seating, and tables. One contact hour of continuing education credit was offered 
to participants. The Cancer Center manager applied for and was approved for one contact 
hour through the Washington State Nurses Association Continuing Education Approval 
& Recognition Program, which is accredited by the American Nurses Credentialing 
Center’s Commission on Accreditation.  
Confidence is the state of feeling comfortable or the belief in one’s ability to do 
something (Merriam-Webster, n.d.). Confidence, or comfort, in performing CIPN 
assessments is a subjective measure expressed by each individual nurse, which this 
program intended to increase through education and practice.     
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Chapter II: Review of Literature and Model of Evidence-Based Care 
Introduction 
 A comprehensive review of available research was performed for current 
literature on CIPN assessment recommendations, practice guidelines, nurses’ role in 
assessment, and nurses’ knowledge of CIPN. Search engines included CINAHL, 
EBSCOHost, Medline, Health Source, and OVID to search articles from 2004-2015 with 
combinations of the following terms: “cancer,” “neoplasms,” “oncology,” 
“antineoplastic,” “peripheral,” “neuropathy,” “peripheral nervous system,” 
“chemotherapy induced peripheral neuropathy,” “screening,” “guideline,” “nursing 
knowledge,” “professional development,” “nurse continuing education,” “staff 
development,” “competency assessment,” “professional competence,” “nurse 
assessment.” Examination of referenced articles also revealed useful literature.  
Exclusion criteria included any literature that focused on medication and 
interventions alone or were written in a language other than English. The Johns Hopkins 
evidence rating scale was used to evaluate the level of evidence in the journal articles 
reviewed (Dearholt & Dang, 2012). The Johns Hopkins rating scale was used to 
determine the strength and quality of evidence. Strength was rated level one through five: 
level one was an experimental study, randomized controlled trial, or a meta-analysis of a 
randomized controlled trial; level two was a quasi-experimental study; level three was 
non-experimental, qualitative, or meta-synthesis; level four was an article of opinion by 
experts based on research such as systematic reviews; level five is opinions not based on 
research such as personal experience or clinical expertise.  
CIPN EDUCATION AND ASSESSMENT  10 
 
The quality of evidence was rated A for high, B for good, and C for low quality or 
major flaws. An explanation was given for what qualifies as research, summative 
reviews, organizational, and expert opinion within the quality rating. The AGREE II 
appraisal tool was used to evaluate the clinical practice guidelines (AGREE, 2014). This 
tool is a 23 item questionnaire used to assess the methodological rigor and transparency 
of practice guidelines with six domains: scope and purpose, stakeholder involvement, 
rigor of development, clarity of presentation, applicability, and editorial independence. 
An evidence table is provided in appendix C. 
The review of literature suggests that CIPN is under-addressed, knowledge 
deficits do exist, and standardized, reliable assessments are needed (Binner et al., 2011; 
Kiser, Greer, Wilmoth,  Dmochowski, & Naumann, 2010; Mann, 2008; Paice, 2009; 
Postma & Heimans, 2000; Stubblefield et al., 2009; Visovsky et al., 2007). Furthermore, 
research indicates that CIPN identification is a safety and QoL issue that needs to be 
more adequately addressed (Cavaletti et al., 2009; Kiser, et al., 2010; Lavoie Smith, 
2013; Mols, et al., 2013; Stubblefield et al., 2009; Tofthagen, 2010). At minimum, the 
review of literature strongly supported the need for further research in CIPN and nurses’ 
roles in assessment of CIPN.  
 Guideline Development 
The NCCN, ASCO, and ONS have all published information on CIPN. Despite 
these publications, no specific guidelines, or gold standard, for CIPN assessment have 
been established in cancer care. These organizations offer key points to include in CIPN 
assessments but do not recommend one specific screening tool. Recommendations 
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include active assessment for CIPN on the part of healthcare workers at baseline and 
throughout treatment, and standardization of assessment to include objective reports, 
neuropathic pain specific scale, functional assessment, and patient questionnaires 
(Griffith, Merkies, Hill, & Cornblath, 2010; Stubblefield et al., 2009; Wickham, 2007). 
Assessment should include a discussion of symptoms along with a numeric scale 
(Hershman et al., 2014).  
A usable screening tool must be easy for healthcare workers to use and have 
minimal cost (Griffith et al., 2010). Binner et al. (2011) discuss that guidelines should be 
developed, but must be efficient and manageable in an already demanding setting. 
Cavaletti et al. (2010) broke down the different CIPN measures into four groups: the 
common toxicity criteria (CTC) scales, functional assessment tools, QoL tools, and 
composite scales. CTC scales include the World Health Organization scale, Eastern 
Cooperative Oncology Group scale, National Cancer Institute- Common Toxicity Criteria 
(NCI-CTC), and the Ajani scale. Currently, if a scale is used by the providers the NCI-
CTC is used. However, not all providers are grading CIPN. The NCI-CTC is commonly 
referred to in drug insert instructions for use, which is one main reason this scale is used.  
Functional assessment tools include the Functional Assessment of Cancer 
Therapy/Gynecologic Oncology Group- neurotoxicity (FACT/GOG-Ntx), Peripheral 
Neuropathy Scale, Oxaliplatin-Associated Neuropathy Questionnaires, Scale for 
Chemotherapy-Induced Long Term Neurotoxicity, and the Patient Neurotoxicity 
Questionnaire.  The only Quality of Life assessment tool specific for CIPN is the 
European Organization of Research and Treatment of Cancer QLQ-CIPN20. Composite 
scales include the Total Neuropathy Score (TNS) and variants of this scale- TNSr, TNSc.  
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The data on all the available tools was limited and not robust (Cavaletti et al., 
2010). The literature recommends combining available tools to cover objective, 
functional, sensory, pain, and patient reported assessments (Cavaletti et al., 2010; Griffith 
et al., 2010; Stubblefield et al., 2009; Wickham, 2007). While awaiting more research on 
CIPN, education for healthcare workers and patients is necessary (Stubblefield et al., 
2009). 
Nurses should be at the forefront of CIPN screening with the use of validated 
tools (Lavoie Smith, 2013). A study of gynecologic oncologists who screened patients for 
CIPN noted a lack of standardization and consistency in grading and reporting of CIPN 
by providers (Kiser et al., 2010). These gaps could be mitigated if nurses were leaders in 
identifying CIPN. Research shows that oncology nurses should be knowledgeable about 
CIPN and play a lead role in educating patients. This may lead to improved QoL and 
appropriate treatments for patients. Because oncology nurses have such a vital role in the 
assessment and management of CIPN, an algorithm was developed for nursing 
(Tofthagen, Visovsky, & Hopgood, 2013). This algorithm was developed from current 
literature and clinical expertise and could be utilized by oncology nurses in the outpatient 
setting. The basis of this method is to query patients at baseline and with every visit 
regarding numbness, tingling, and/or discomfort. Additional assessment is warranted 
based on changes from the previous assessment. 
Symptom Management and Quality of Life 
Patients (n=14) were surveyed regarding neuropathic symptoms experienced 
while receiving chemotherapy. Information was gathered on non-painful symptoms, 
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painful symptoms, and effects on daily life. The results indicate that there is a vast array 
of symptoms that are not always easy to describe (Tofthagen, 2010). The most common 
non-painful symptoms included numbness (100%), loss of balance (57%), muscle 
weakness (57%), and tingling (50%). More than half (57%) of the patients reported that 
symptoms interfere with daily life. The majority (71%) also reported pain; however, the 
description of pain varied with the most common responses of burning, muscle aches, 
and pins and needles. Of concern, half of the patients surveyed reported falls or injuries 
related to reduced sensation.  
Not all side effects of chemotherapy and cancer can be completely mitigated, but 
great effort must be put towards the best symptom management available as to give 
patients the best QoL. A higher number of neuropathy symptoms reported correlates to 
worse functional status and lower QoL (Mols et al, 2013). Griffith et al. (2010) believe 
CIPN is the primary dose-limiting toxicity for numerous chemotherapeutic agents, 
leading to decreased physical functioning and QoL. Pain management and strategies to 
maximize physical function must be incorporated into patient care, especially considering 
there is no current prevention or treatment options for CIPN (Tofthagen et al., 2013). 
Additionally, neuropathic pain is often resistant to typical pain management strategies 
(Mann, 2008). Close attention should be given to CIPN to avoid any unnecessary 
suffrage in cancer patients. 
Patients may not even know they have CIPN. Subtle clinical signs of CIPN, such 
as decreased vibratory sense, change in temperature sensations, and pinprick sensation 
exist prior to patient reported symptoms and physical disabilities (Lavoie Smith, 2013). 
Limited patient awareness of symptom emphasizes the need for clinical assessment for 
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early detection of CIPN. Considering that CIPN can be a long lasting side effect of 
chemotherapy (Mols et al, 2013; Tofthagen, 2010), the intent of treatment, palliative 
versus cure, must be determined as this may help determine the acceptable level of CIPN 
and resultant side effects. Patients may tolerate more CIPN if the tradeoff is a disease free 
state (Wickham, 2007). Additionally, patients may be reluctant to discuss CIPN due to 
fear of dose limitations which may affect overall survival (Paice, 2009). Education of 
patients, open discussions with providers, and mutual decision-making can alleviate these 
fears. Simply listening to the patients and trusting their concerns is empowering to 
patients and breaks down barriers for proper assessment, early detection, and 
management (Hershman et al., 2014; Mann, 2008). 
Nurses and Education 
The literature shows that nurses need more education regarding CIPN, how it 
affects patients, and how to screen patients. Binner et al. (2011) indicate that there is a 
knowledge gap regarding CIPN, and nurses have low confidence in their ability to 
accurately perform CIPN assessments. Only fifteen percent of the nurses in the study 
believed they received previous instruction on how to perform an assessment for CIPN 
(Binner et al., 2011). Lavoie Smith (2013) believes nurses are aware that CIPN is an issue 
for patients, but unaware how to act on this knowledge. Nurses should be educated on 
CIPN and should take an active role in assessment and management.  
Although comprehensive assessments and diagnosis by nurses are out of the 
scope of practice, short and concise assessments, education, and symptom management 
are all roles that nurses can undertake (Mann, 2008; Maxwell, 2013; Paice, 2009; 
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Wickham, 2007). Therefore, nurses were the ideal modality for education and assessment 
for CIPN. Some elements of CIPN assessment are not as widely known by nurses. For 
example, nurses generally do not have adequate training on the use of a tuning fork and 
assessing muscle strength (Lavoie Smith, Beck & Cohen, 2008). Following specialized 
training, oncology nurses could learn to screen for CIPN in patients. Further education 
for nurses and research on the accuracy of nurse assessments for CIPN is needed (Lavoie 
Smith et al., 2008). Educating nurses can improve the care and outcomes of patients 
(Maxwell, 2013).  
Nurses are also ideally suited for assessment of patients for CIPN given that they 
are the frontline managers of care prior to receiving chemotherapy (Maxwell, 2013). 
Nurses must assess patients prior to administration of chemotherapy and report any 
concerning findings to the provider. This allows for one last check that may avoid 
worsening CIPN due to the administration of neurotoxic chemotherapy. 
Gaps in Evidence 
Stubblefield et al. (2009) believe CIPN is an under-researched, adverse event 
made more difficult by multi-agent chemotherapy regimens, pre-existing conditions, lack 
of standardized screening, and inadequate patient education. The NCCN task force also 
believes research has focused on treatment response and survival, rather than side effect 
issues such as CIPN. The gap in data makes it difficult to define the prevalence of CIPN 
(Kiser et al., 2010). Lavoie Smith (2013) notes the incidence of CIPN is somewhere 
between eight and 83% in phase III clinical trials with taxane administration, a known 
neurotoxic chemotherapy, indicating the prevalence of CIPN is not well established. 
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ASCO supports the need for more reliable research with larger sample sizes, 
especially given that it was unable to identify consistent or definitive evidence to support 
prevention or treatment strategies (Hershman et al., 2014). Evidence-based 
recommendations by the ONS regarding CIPN interventions support that there are no 
recommended nursing prevention or treatment strategies supported by research (Visovsky 
et al., 2007). The ONS believes there needs to be more research with rigor, 
standardization, and adequate sample size. In the meantime, nursing interventions of 
patient education and support in the following areas are recommended: signs and 
symptoms of PN, communication with provider, personal safety, foot care, risk for 
ischemia and thermal injury, and management of autonomic dysfunction. 
 Numerous screening tools have been developed, yet no gold standard exists for 
evaluation of CIPN (Stubblefield et al., 2009). There is a great need for more robust 
studies on the measurement of CIPN and standardized screening (Griffith et al., 2014; 
Hershman et al., 2014; Visovsky et al., 2007). Many articles support CIPN assessments 
done by nurses (Binner et al., 2011; Kiser et al., 2010; Lavoie Smith, Cohen, Pett, & 
Beck, 2011; Lavoie Smith, 2013; Mann, 2008; Maxwell, 2013; Tofthagen, 2010; 
Tofthagen et al., 2013), yet there is little evidence to support that nurses are 
knowledgeable and trained to do so (Binner et al., 2011; Lavoie Smith et al., 2008). There 
is also minimal research available on how to increase nurses’ confidence in performing 
CIPN assessments. Experts agree that CIPN is an issue that needs to be addressed; 
however, the practice incorporation of screening is lacking (Binner et al., 2011). 
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Implications for Practice 
Based on available literature, it is recommended that all oncology nurses receive 
training on CIPN. Nurses are educated as generalists to care for all ages and conditions. 
Specialties, such as oncology, must train nurses to care for specific populations and 
conditions. Training may occur within a practice or through national organizations and 
certifying bodies. Because CIPN affects such a large number of patients in the oncology 
setting, CIPN-specific training should be offered. This important education was missing 
in the education of oncology nurses in the Cancer Center. 
It is also recommended that all patients be assessed at baseline, with subsequent 
treatments, and with every oncology follow up after receiving neurotoxic chemotherapy. 
Nurses should screen patients with an approved tool that is reliable and valid.  Because 
nurses cannot diagnose or manage CIPN, a notification system should be in place to alert 
the providers of the assessment results. 
Model of Evidence-Based Care 
 Clinical practice decisions are not solely based on research, but rather experience 
from healthcare workers and patients also contribute to determining best practice. The 
combination of research and experience is called evidence-based practice (EBP) 
(Dearholt & Dang, 2012). EBP involves improving efficacy, efficiency, and effectiveness 
of healthcare while analyzing the risks, benefits and costs. The desire of this project was 
to develop an EBP change through the education of nurses on CIPN to improve the care 
and outcomes of oncology patients.  As indicated in the literature review, the available 
research is somewhat limited for this topic. However, the expert opinions presented 
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within the research do support the need for identification of CIPN and for nurses to 
perform the assessment (Binner et al., 2011; Kiser et al., 2010; Lavoie Smith et al., 2011; 
Lavoie Smith, 2013; Mann, 2008; Maxwell, 2013; Tofthagen, 2010; Tofthagen et al., 
2013). The providers within the Cancer Center of interest also desire the implementation 
of this project. Therefore, the combination of the available literature on CIPN and a 
desire to improve care are the basis for this EBP change. 
The Iowa Model of Evidence-Based Practice was used to guide this innovation 
project. This model was chosen because of its widely recognized use by healthcare 
organizations in the process of implementing EBP changes to improve healthcare 
outcomes. The Iowa model was comprised of a series of trigger questions. These trigger 
questions follow a stepwise approach to determine the relevance to an organization, if 
there is research evidence to support a practice change, if a pilot change is appropriate, 
practice wide change, and continued monitoring of outcomes (Burns & Grove, 2005, p. 
626-631). This model was also well suited for the evaluation of knowledge, abilities, and 
attitudes of those involved in EBP changes. Nurses desire the highest quality of care for 
patients, but believe they need more education and time to convert evidence into practice 
(Brown, 2014). The Iowa model’s stepwise approach can be used by nurses to implement 
EBP changes (Figure 1). This project was merely the beginning steps in the 
implementation of EBP change. 
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Figure 1. The Iowa Model of Evidence-Based Practice to Promote Quality Care. by Titler 
et al., 2001. Reprinted with permission from the University of Iowa Hospitals and Clinics 
and Marita G. Titler, PhD, RN, FAAN. Copyright 1998.  
The first step of the Iowa Model was to identify the problem. In this project the 
problem was a perceived knowledge deficit regarding CIPN and the lack of formal 
assessment of patients for CIPN. The second step was to determine the priority level of 
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the problem. This project was considered moderate priority because the risk for not 
implementing this change was fairly low, yet the desire to provide the best care for 
patients was high.  
Identifying the team was the next step. Team members for this project included 
one certified nurse practitioner (CNP), two nurse managers, the clinic director, and a 
South Dakota State University (SDSU) faculty advisor. All team members expressed a 
desire to implement this project. A PICOT question was formed, a literature review was 
done, and desired outcomes were identified. The paucity of research did not deter the 
team. The level of available evidence was relatively low, but the project was still 
justified, as it was believed that this project was low risk but could offer great benefits to 
the patients and the Cancer Center.  
The next step in the Iowa model was to perform a pretest of nursing knowledge 
and confidence. Nursing education on CIPN and patient assessment took place and a 
posttest was performed. Nurses were then considered trained and expected to assess 
patients for CIPN. The project underwent continuous evaluation with changes as needed. 
After three months an additional nursing knowledge and confidence posttest was 
performed, along with project evaluation. At this point it will be determined if formal 
assessment for CIPN should be developed and implemented. Dissemination of the results 
will take place for possible CIPN assessment organization wide and possibly in other 
cancer centers. 
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Adult Learning Theory 
This innovation project proposed to educate nurses about CIPN so proper 
identification of CIPN can take place for patients receiving neurotoxic chemotherapy. 
The Adult Learning Theory was used to guide this project. Adult learning, or andragogy, 
was studied by Malcolm Knowles who believed there are five underlying assumptions: 
adult learners are independent and self-directed, life experiences influence learning, 
social roles and learning are related, adult learners are interested in applicable and 
problem-focused learning, and adults have internal motivations for learning (Merriam, 
2002). Additionally, Knowles developed four principles of andragogy (Figure 2). These 
include the need to be involved in the education process, incorporation of the learner’s 
previous experiences, relevance and impact on the learner, and problem-centered 
education.  
To be in alignment with these assumptions and principles, the educational session 
was offered at two different times and simple options were given to the learners for 
independence in style of learning- handouts and writing tools, visual PowerPoints, and 
discussions. This will help to foster respect, support, and autonomy in learning (Merriam, 
2002). Open communication and dialogue with the nurses was used to promote approval. 
The nurses’ previous knowledge was gathered through a pre-test and was used to form 
the educational session to build on. Evaluations were done in the form of a posttest, 
which nurses were able to review. For the nurses to relate the importance of the 
education, background information and impact on patients was given to the nurses. The 
hope was that if nurses could see the impact this education and identification of CIPN 
could make on patients, they would more likely to adapt to the change. Also, the 
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immediate application of knowledge through CIPN assessments should help in the 
adaptation to change. 
 
Figure 2. Malcolm Knowles Adult Learning Theory. Reprinted from “The Adult 
Learning Theory- Andaragogy- of Malcolm Knowles” by C. Pappas, 2013, from 
http://elearningindustry.com/the-adult-learning-theory-andragogy-of-malcolm-knowles. 
Reprinted with permission.  
Change Theory 
In 1962, Everett Rogers published his first book on the change theory, Diffusion 
of Innovation. Since then, the theory has been used around the world with numerous 
disciplines and countless innovative projects. From the time new research is unveiled or a 
new process is developed, it can take years to spread the information for the benefit of 
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others (Rogers, 1995). One reason the theory is widely known is because it aims to 
improve the time it takes to disperse the knowledge of an innovative change.  
Diffusion is the process of communicating new ideas to others in a group in order 
to make mutual decision (Rogers, 1995). This change theory is applicable because the 
aim of this project was designed to deliver knowledge about CIPN and the need for 
identification of patients in order to improve care for patients. CIPN education and 
assessment for nurses is a new idea in the Cancer Center given there is a perceived 
knowledge deficit and lack of formal assessment.  
Roger’s (1995) four components were used in this project: innovation, 
communication, time, and social system. Nurses in the Cancer Center were educated on 
CIPN and assessments which was anticipated to improve the knowledge of nurses. 
Knowledge was retested after three months to test for retention, knowledge gaps, and 
confidence. This project is expected to contribute to the innovation-decision making for 
future formal implementation of assessment of patients for CIPN. 
The rate of adoption by the nurses is an important factor for the long term success 
of CIPN assessments. It was anticipated that the innovators would be influential team 
members. A desire to provide better care to patients and continuing education contact 
hours were expected to influence the nurses in the early adopters and early majority 
categories. The late majority and laggards (Rogers, 1995) may have needed more time to 
accept the knowledge and see the need to identify patients with CIPN. The majority of 
the nurses who adopted the change helped encourage the late majority and laggards and 
continue the process of educating these nurses.  
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Chapter III: Project Design and Methodology 
Introduction 
  EBP is the incorporation of best available research, practitioner experiences, and 
patient needs into high quality and cost-conscious care (Burns & Grove, 2005). EBP is 
essential for improving healthcare and patient outcomes. This EBP change was intended 
to increase the knowledge and confidence of nurses in their care of patients with, or at 
risk for, CIPN. It has the potential to improve the care and outcomes of patients who 
receive known neurotoxic chemotherapy agents. 
Population 
  The population studied was a convenience sample of nurses employed in an 
outpatient Cancer Center in a large Midwest city. The Cancer Center contains a clinic 
where provider office visits are conducted and an infusion center where treatments are 
given. At the time of the project initiation there were 10 nurses that primarily worked in 
chemotherapy infusions, and 10 nurses that worked primarily in the providers’ offices. 
Several of these nurses have cross training to both areas. There are also four CNPs 
employed by the Cancer Center that care for patients in the clinic, infusion center, and 
hospital. All nurses had some college level education, between two to six years of 
college. Approximately half of the nurses were oncology certified and 
chemotherapy/biotherapy certified. Years of nursing experience ranged from 0-20 years. 
Most of the nurses worked full time. The majority of the nurses were Caucasian. 
 According to the 2010 census, the state in which the Cancer Center is located is 
84.7% Caucasian (United States Census Bureau, 2014). Additional races served include 
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African American, American Indian, Hispanic, and Asian. The percentage of persons 25 
years or older who are a high school graduate or higher is 90.1%, while those with a 
bachelor’s degree or higher is 26%. 
Setting 
 The setting for this project was the Cancer Center- an adult outpatient medical 
oncology center and infusion center in a large Midwest city which serves a large 
geographic region, including urban, rural, and frontier population. Demographics of 
patients at this clinic were primarily Caucasian, middle class, and 18 years old and older. 
The center included six oncologists, four CNPs, four pharmacists, and multiple other 
support staff. Services offered within the Cancer Center included doctors’ offices, cancer 
treatment administration, pharmacy, lab, palliative care, psychiatry, and research studies. 
This project was well suited for this Cancer Center because no standard existed in this 
clinic for CIPN assessments, and providers expressed a desire to implement a formal 
assessment process.  
Design  
This practice innovation project was a quasi-experimental one-group pretest 
multiple posttest design. Questionnaires with multiple choice questions were used to 
gather the pre and posttest data (Appendix D). The pre and posttests were identical. 
Advantages of the one group pretest multiple posttest design included identification of 
baseline knowledge, as well as comparison of pre and post-education knowledge (Burns 
& Grove, 2005). The simple structure and simple analysis of data was also an advantage 
to this design. Disadvantages include maturation from pretest to posttest not attributable 
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to the education, no comparison group or independent variable, and the lack of 
generalizability (Burns & Grove, 2005). 
Participant Recruitment 
  Participants were recruited from nurses and CNPs who worked at the oncology 
center. Approximately two weeks before the education, the project leader emailed all 
nurses with an overview of the project, including timeline, objectives, and contact 
information. One week prior to the education, fliers were hung in the break room and an 
email was sent to all nurses from a Cancer Center manager which included the date, 
times, objectives of the education, and contact hour information. Two sessions were 
offered, one at 7:30 am and one at 4:30 pm, to optimize nurses’ ability to attend. These 
scheduled times were the standard format for nursing education in the Cancer Center. 
Participation in the project was not be mandatory, but was be highly encouraged. One 
contact hour was given to nurses who attend the educational session. A Cancer Center 
manager completed the application process for the contact hours and approval was 
received. 
Development of Education 
 Education content was compiled from available literature and clinical expertise.  
No standardized education content or format for nurses on CIPN existed at the time of 
this project. Content for education included pathophysiology, significance, associated 
factors, prevention, management, methods for assessment, and patient education. 
Additional emphasis was given during the education based on the pretest results to ensure 
deficient areas were well discussed. Education on performing CIPN patient assessment 
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was also done through discussion and hands on demonstrations. The CIPN patient 
assessment consisted of already existing resources, based on clinic preference, and ease 
of assessment for the nurses. Education format was based on the common format of 
education for the clinic. Handouts were given to the nurses containing step by step 
information on the CIPN patient assessment process. The four principles of the Adult 
Learning Theory (Merriam, 2002) helped guide the education format development by 
involving the nurses in the education process, incorporating nurses’ baseline knowledge 
and experience of CIPN, identifying why this education is relevant, and identifying CIPN 
as a problem while working towards improving patient care. 
Intervention  
The intervention was an educational session for nurses on CIPN and CIPN 
identification. Nursing knowledge and confidence was tested. A pretest was administered 
to nurses to determine baseline knowledge of CIPN and their confidence in performing a 
patient assessment for CIPN. Gaps in knowledge that were identified from the pretest 
were incorporated into and emphasized in a one hour educational session on CIPN. 
Nurses were also taught how to identify patients with CIPN through PowerPoint 
discussion and hands on learning. The education was in the form of a PowerPoint 
presentation, discussion, and demonstration. Following the education, nurses were again 
tested on their knowledge and confidence to compare from baseline before the education. 
An additional posttest was administered three months after the initial education. This 
posttest served as a measure of knowledge retention and change in confidence.   
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Instruments 
Demographic information was obtained at the time of the pretest (Appendix E). 
No standardized tests for nursing knowledge on CIPN existed at the time. The pretest and 
posttest were identical and were developed from available literature and clinical expertise 
(Appendix D). Nurses’ confidence in identifying CIPN was also measured in the pretest 
and posttests. CIPN signs and symptoms, common patient reports, common causes, and 
treatments were included in the tests, which supports the content validity of the tests 
because of the broad range of knowledge tested on CIPN.  Face validity was tested with 
four inpatient oncology nurses not directly involved with this project, and their 
conclusion was that the pre and posttests were at least adequate for measuring nursing 
knowledge and confidence. Reliability was established through review of the pretest and 
posttest by a provider highly knowledgeable in CIPN. It was not feasible to fully test 
validity and reliability prior to the start of this project due to time constraints and 
resources available. 
At the time of the project, the Cancer Center was not interested in implementing 
additional screening instruments in full. The Cancer Center implemented the Distress 
Thermometer (Appendix A) in March of 2014, and it was felt that the available 
functional assessments were too lengthy and contained duplicate questions. The 
institution agreed to pull the neurotoxicity questions from the FACT/GOG-Ntx 
(Appendix F) and add these with the Distress Thermometer, which are both self-
administered screenings. The Cancer Center believed combining the Distress 
Thermometer with neuropathy specific questions from the FACT/GOG-Ntx (Appendix 
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F), a thorough pain assessment, and simple function and sensory testing was adequate 
and appropriate based on the evidence reviewed. 
Following review of available literature and published guidelines, a simple five 
component assessment was compiled. The five components included patient self-report, 
quality of life screening, sensory testing, functional testing, and a clinical grading system. 
The Distress Thermometer and the FACT/GOG-Ntx was to be given to all cancer patients 
at registration to fill out independently.  Nurses were to record the self-administered 
screening results in the electronic medical record (EMR). Pain assessments will continue 
to be recorded as before, with additional emphasis on neuropathic pain. Sensory testing 
was to be done with two point discrimination using a paperclip. Functional testing was to 
be done by asking each patient to pick up a small paperclip from a flat surface. This 
information was to be recorded in the EMR in a progress note for the visit which was to 
be used to communicate to the provider. With the information gathered, the hope was that 
the providers who saw the patient could easily assign a clinical grade, specifically the 
NCI-CTCAE, to each patient. The assessment process was modified throughout the 
project to better accommodate the nurses and providers, and to better assess the patients. 
Modifications are discussed in chapter four.  
Education for nurses was the essential first step to CIPN assessments so the 
nurses better understood CIPN, the importance of identification, and how to administer 
an assessment. Nurse education was step one in the process of improving care for patients 
with CIPN. This project positions the Cancer Center for further research and EBP in 
patient assessments for CIPN conducted by nurses.  
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Protection of Human Subjects  
 Approval from the SDSU Human Subjects Committee was obtained (Appendix 
G), as well as the Institutional Review Board of the organization where the project took 
place (Appendix H). Written approval from the Cancer Center director and the Chief 
Nurse Executive was obtained prior to initiation of this project. Consent of the 
participating nurses was implied by their voluntary participation. Results from nursing 
demographics and testing were kept secure at all times. This project was considered low 
risk with potential important benefits for nurses and patients. No patient data was 
obtained or analyzed for this project. 
Project Analysis 
Different measures were used to analyze the data collected. Questions one 
through five were Likert scale format. T-tests were used to test the mean scores and 
determine if there is a significant difference between the pretest and posttests with 
statistical significance set at 0.05 (Burns & Grove, 2005). One-way ANOVA was used to 
test the difference between the means of the pretest and posttests (Burns & Grove, 2005). 
Questions six through 23 were knowledge questions; the averages of the scores correct 
pre and posttest were recorded and analyzed. Descriptive statistics were used to analyze 
demographic data. Demographic information on the participating nurses was gathered, 
including the following information: age, gender, ethnicity, education, employment 
status, primary work area, years of nursing experience, years of oncology experience, 
oncology certification, chemotherapy and biotherapy certification, and previous formal 
training on CIPN. 
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Environmental and Organizational Context 
Nurses are expected to be able to assess and identify adverse symptoms from 
cancer and chemotherapy. Education is offered on a regular basis in the Cancer Center 
for nurses on types of cancer, medications, and symptom management. Prior to this 
project education had never been offered specifically on CIPN, which made this project 
novel and significant for this clinic.  
Assessment tools available for nurses in the Cancer Center that may be applicable 
to CIPN include a pain assessment flow sheet, the NCCN Distress Thermometer, and a 
nurse-driven triage protocol on neuropathy. These assessment tools do not allow for 
thorough assessment of CIPN. Additionally, no education or formal implementation of 
the nurse-driven triage protocol has been conducted since development. The areas 
missing from the assessment tools prior to this project were function, motor, and sensory 
assessment. To properly assess for CIPN, a better focused assessment incorporating 
available tools, missing assessment areas, and compilation of information in one place in 
the EMR should be developed, educated on, and implemented. This project paves the 
way for a future CIPN screening protocol. 
This project was also important to the Cancer Center because there was no current 
standardized education for patients regarding CIPN. Patients are given informational 
handouts developed by the National Institute of Health entitled Managing Chemotherapy 
Side Effects: Nerve Changes, and Managing Chemotherapy Side Effects: Pain on their 
first day of chemotherapy if they receive a neurotoxic chemotherapy. Given the perceived 
CIPN EDUCATION AND ASSESSMENT  32 
 
nurses’ knowledge deficit and lack of standardized patient education, this project will 
help nurses be prepared to educate patients.  
The Cancer Center is dedicated to exceptional care, research, and advancing the 
care of cancer patients. This project aligns with these values because it has the potential 
to improve the care through education of nurses and research based interventions. The 
clinic administration was supportive of this project as they seek to increase education of 
nurses and to improve the care of patients. Patients also desire improved symptom 
management and care. Healthcare is competitive and patients will seek out the best care 
available.  
Stakeholders and Facilitators 
 Key stakeholders of this project within the healthcare system included physicians, 
CNPs, nurses, and management from the Cancer Center. Patients and families were also 
stakeholders as they serve to benefit from the education and process change within the 
clinic related to improved identification of CIPN. This should translate into improved 
care and outcomes for patients.   
 One CNP was identified as the primary facilitator who helped form the 
committee, advocate for the project, and develop the nursing education and testing. She 
had a strong interest and extensive education in symptom management. All of the 
providers at the Cancer Center expressed an interest and support of the project. 
Management and nurses also expressed their desire to support and assist in this project.  
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Anticipated Barriers  
 Anticipated barriers included resistance from nurses who may not perceive value 
in the education and assessment of CIPN due to the time involved. While research 
indicates that nurses desire to EBP changes and improved care for patients, lack of time is 
frequently cited as a barrier to EBP change (Melnyk, Fineout-Overholt, Gallagher-Ford, 
& Kaplan, 2012). Sustainability of the assessments following the education was also a 
perceived barrier, primarily related to nurses’ resistance. Lack of support from leadership 
may also be a barrier to EBP implementation (Melnyk et al., 2012), which could directly 
affect nursing time and sustainability. If the Cancer Center leadership is not supportive 
and does not allow nurses to take the time to become more educated or to assess patients, 
this project will not be sustainable. 
With an already small sample size, nurses who chose not to participate in the 
project were a perceived barrier to interpretation of the results. Attempts to overcome 
these barriers were made through nurse input, contact hours credit for the education, and 
positive reinforcement from the project leader and stakeholder. The education, itself, was 
a means to break the barriers as it intended to educate nurses on the prevalence of CIPN 
and the quality of life concerns for patients. 
 With the lack of concrete recommendations from guidelines, choosing an 
assessment method was a barrier. It was important for the nurses and providers to come 
to a consensus on what assessment components to use and how to communicate the 
results to the providers. Additionally, having the screening tool in the EMR would have 
been ideal for ease of data input, comparing from assessment to assessment, and 
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interpretation by the providers. This was not realistic or feasible prior to the project 
implementation. Historically, it can be difficult and time consuming to have changes 
made to the EMR charting formats. Although this wasn’t necessarily a barrier to the 
implementation of education, it did prevent ideal compilation of assessment results. EMR 
documentation will be an area to focus on in the sustainability process. For the purpose of 
this project, a “dot phrase” template was created for data input into the chart and entered 
into a progress note in the patient encounter.  
Organizational Impact 
This project has the potential of positively financially impacting the organization. 
Nurses who are better educated can provide better care. Patients whose symptoms are 
well managed may have lower healthcare costs. Patient satisfaction scores may also be 
impacted if patients feel they are receiving better care. Patient satisfaction is increasingly 
being measured and reported publicly, and may impact reimbursement.  
Policy implementation based on research and EBP is vital to healthcare. Through 
the literature identified in this project and the results of the nurse education, a novel CIPN 
assessment strategy process could be developed. These patient assessments may 
positively impact patients through early identification of CIPN so proper management 
can take place. This project may open the door to further policy implementation of CIPN 
screening, which can be modified with future literature recommendations. 
Rural and underserved patients are treated on a daily basis in this Cancer Center. 
The region the Cancer Center serves is primarily rural. Geriatric patients were one 
underserved population that was impacted by CIPN assessment and identification. 
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Approximately 46% of cancer survivors are older than 70 years of age (American Cancer 
Society, 2014). Cancer survivors are living longer and the elderly population is growing. 
With cancer patients living longer, and the need to care for a larger elderly population, it 
is important to provide the best possible, evidence-based, care to these patients to prevent 
years of unnecessary suffering. 
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Chapter IV: Results and Analysis 
Introduction 
 The population studied was a convenience sample of nurses employed by the 
Cancer Center who voluntarily participated in education on CIPN and were asked to 
complete a pretest and two posttests. The pretest was distributed to all nurses in the 
Cancer Center one week prior to the education session. Nurses were allowed to turn in 
the pretests up until the time of the education. The posttest was distributed at the 
completion of the education program, handed out with the contact hours. The second 
posttest was distributed three months after the education session to all nurses who 
attended the education session. Pretests returned with demographics totaled 20, with 16 
first posttests, and 12 second posttests returned.  
Demographics 
Of the 20 demographic surveys that were returned, 11 worked primarily in the 
clinic and nine worked primarily in the infusion center. The mean age surveyed was 32.2. 
Ninety percent surveyed were female and all identified as Caucasian. All nurses have 
some college level education: two certificates, eight associates, six bachelors, four 
masters or higher (Figure 3). Seventeen nurses surveyed were full-time employees and 
three were part-time. The majority of the nurses had between three and 11 years of 
nursing experience and less than six years of oncology experience (Figure 4). Nineteen 
nurses were chemotherapy/biotherapy certified and 10 were Oncology Certified Nurses. 
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All nurses surveyed marked that they had never had previous formal training on CIPN. 
 
Figure 3. Education level of nurse participants.  
 
Figure 4. Years of experience of nurse participants. 
Project Outcomes   
Nursing knowledge. The range of correct answers on the pretest was 10 to 17 out 
of 18 questions with a mean score of 13.7 (SD 2.05). The range of correct answers on the 
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first posttest was 13 to 18 with a mean score of 16 (SD 1.55). The range of correct 
answers on the second posttest was 10 to 17 with a mean score of 15.33 (SD 1.78) (Table 
1). The improvement in scores was statistically significant from the pretest to the first 
posttest (p<0.01), and from the pretest to the second posttest (p= 0.025) (Table 2).  There 
was a statistically significant difference between the groups as determined by one-way 
ANOVA (F(2,45)=7.515, p<0.01) (Table 3). 
Table 1 
 
Knowledge Mean and Standard Deviation 
 Range Mean Standard Deviation 
Pretest 10-17 13.7 2.05 
1
st
 Posttest 13-18 16 1.55 
2
nd
 Posttest 10-17 15.3 1.78 
 
Table 2 
 
Knowledge Statistical Significance 
 T value p value 
Pretest and 1st Posttest -3.82774 0.000529 
Pretest and 2
nd
 Posttest -2.37319 0.025312 
1
st
 Posttest and 2
nd
 Posttest 1.03784 0.310618 
  
Table 3 
 
ANOVA 
  
 SS Df MS F P 
Between 50.027 2 7.467 7.467 0.002 
Within 150.737 45 3.350   
Total 200.764 47    
 
Confidence. Confidence in nurses’ knowledge and ability was assessed on a 
Likert scale with five being very confident, three was somewhat confident, and one was 
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not confident at all. The range of confidence on the pretest was 1.5 to 4.  The range of 
confidence on the first posttest was 1 to 5 and 3 to 5 on the second posttest. The mean 
confidence level on the pretest was 2.94, first posttest was 4.00, and second posttest was 
4.13. Individual confidence increased with each test except for one nurse who initially 
marked 1-2 on the pretest for confidence in ability to perform CIPN assessment and 
marked 1 on the first posttest. No second posttest was received for this nurse. This was 
the only nurse that marked 1 for confidence. Statistical significance was reached in the 
increase in overall confidence from the pretest to the second posttest (p= 0.0457) (Table 4 
and Table 5). 
Table 4 
 
Confidence Range and Mean 
 Range Mean Standard Deviation 
Pretest 1.5-4 2.94 0.80 
1
st
 Posttest 1-5 4 0.80 
2
nd
 Posttest 3-5 4.13 0.54 
 
Table 5 
 
Confidence Statistical Significance 
 T value p value 
Pretest and 1st Posttest -6.17382 0.102228 
Pretest and 2
nd
 Posttest -4.51567 0.045705 
1
st
 Posttest and 2
nd
 Posttest -0.57324 0.668633 
 
 Application of knowledge. Additional questions were included in the test in 
Likert scale format from one to five in regards to how important the nurses felt CIPN 
assessments were, how often assessments were being done, and the likelihood of 
performing CIPN assessments. The means for importance were 4.65 pretest, 4.27 first 
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posttest, and 4.58 second posttest. The means for frequency of assessments for the 
pretest, first posttest, and second posttest were 3.74, 4, and 3.67 respectively. The means 
for likelihood of assessing patients were 4 pretest, 4.56 first posttest, and 4.25 second 
posttest (Table 6). One nurse had marked on the pretest that CIPN assessments were done 
on every patient and subsequently marked on the first posttest “I don’t know how to 
assess CIPN.” A second posttest was not completed by this nurse.  
Table 6 
 
Application Mean 
 Importance Frequency Likelihood 
Pretest 4.65 4.27 4.58 
1
st
 Posttest 3.74 4 3.67 
2
nd
 Posttest 4 4.56 4.25 
 
 Anecdotal information. Nurses were queried with both posttests if they felt their 
knowledge had increased since the time of the education and all answered either 
somewhat or definitely. Nurse managers and providers approached the project leader with 
information that they had noticed an increase in identification of CIPN by nurses. The 
nurses also had positive feedback to the managers about the knowledge they gained with 
comments such as “I’m glad I know the chemotherapy medications better now,” and “I 
had no idea that certain disease put a person at higher risk for neuropathy.” During 
discussions about continuation or modification of CIPN assessments by nurses one nurse 
stated “Even if we can identify one person with neuropathy we’ve made a difference. 
There is value in assessing all chemotherapy patients for CIPN.”  
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Chapter V: Discussion of Outcomes 
Discussion 
 The purpose of this project was to evaluate effect of an educational program on 
the knowledge of oncology nurses regarding CIPN and their confidence level with 
assessing CIPN before and after an educational session. The PICOT question and the 
clinical questions were answered with this project. The effect of education and hands on 
demonstration was that there was an increase in knowledge and confidence. Following 
the education session nurses expressed an increase in knowledge about CIPN and 
confidence in assessing patients for CIPN. The three month timeframe from the education 
to the second posttest was attributable to very little loss in knowledge and marginal 
increase in confidence. The overall increase in knowledge and confidence indicates 
nurses’ ability to provide better care and identify CIPN earlier. Interpretation of results 
from pretest to the second posttest was made difficult by a 40% decrease in response rate.  
There was a positive effect on nursing knowledge of CIPN from baseline to the 
three month posttest. There was an increase in knowledge from baseline to the first 
posttest and baseline to the second posttest. There was statistical significance in the 
increase in knowledge for both pretest to first posttest and pretest to second posttest. The 
content and presentation of the education on CIPN was in a format that was easy to 
understand and gain knowledge from. The format of the education eased access and 
encouraged attendance. The contact hours were a positive incentive for education 
attendance. There was a slight loss in knowledge from the first posttest to the second 
posttest with mean scores decreasing from 16 to 15.33 respectively. Loss of knowledge 
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could be attributed to regression and the time from education to the second posttest. 
Distribution of notes with key education points or distribution of the PowerPoint itself 
may have provided access for a knowledge refresher as nurses felt the need. This could 
be considered as an option for future education.  
There was a positive effect on nursing confidence in assessing patients for CIPN 
from baseline to the three month posttest. While not statistically significant, the mean 
score for overall confidence from pretest to first posttest did increase. It’s possible that 
nurses needed more hands on experience with assessments prior to feeling confident. 
This is evident in the statistically significant increase in confidence from pretest to the 
second posttest. An increase in awareness of the need for assessment may also be 
attributed to the increase in confidence.  
The results of this project support the available literature in finding that nurses do 
not receive adequate training on CIPN. Despite the fact that all but one nurse had 
chemotherapy-biotherapy training, and half were Oncology Certified Nurses, none had 
received formal training on CIPN. This project also supports the literature in recognizing 
that CIPN is important and that nurses can be taught how to perform assessments. While 
not formally evaluated, nurses did express to the project leader agreement with literature 
that for sustainability any assessment of CIPN by nurses has to be fairly simple and quick 
to perform.  
The results are also in alignment with previous literature in that prior to CIPN 
specific education, nurses are not overly confident in their knowledge or ability to assess 
patients for CIPN. Nurses do not get adequate training for specialty assessments during 
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nursing school. On the job education and training for medical specialties is needed to 
supplement the nursing school general education. To become confident in specialty 
assessments, nurses need to perform multiple assessments over a period of time. This 
project was important to educate nurses about CIPN and instruct them on how to identify 
those at risk for and those who currently have CIPN. Routine education on CIPN should 
take place in the Cancer Center, as well as other oncology areas, so that nurses are more 
knowledgeable and confident in their assessments of patients. 
Reflections  
 Evidence-based care is a constantly evolving process. There was an increase in 
nursing knowledge and confidence, and there were beneficial modifications to the patient 
assessment process; however, further education and process refinement needs to be done. 
According to the Iowa Model, this project is not ready for adoption. Further evaluation of 
the quality of care given and new research as it becomes available should be incorporated 
into another pilot project on nursing knowledge, confidence in assessments, and patient 
assessments of CIPN.  
The Adult Learning Theory was, indeed, helpful in this project (Merriam, 2002). 
The nurse learners were actively involved in their own education and they were given a 
choice to be involved. Some lead nurses were increasingly involved in modification and 
sustainment of the patient assessment portion, thus providing autonomy and ownership in 
the process. The education was developed based on what the nurses already knew and 
was expanded beyond the baseline while incorporating old and new skills. Nurses agreed 
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that assessing CIPN was important, which therefore, endorsed the relevance and impact 
on the learner, and problem-centered education. 
The Diffusion of Innovation theory (Rogers, 1995) has helped and will continue 
to help the progress of this project. By continuing to communicate ways to improve 
nursing education and patient assessments, this small scale project can be perfected in a 
shorter time in order to be applicable on a larger scale. This supportive social system 
within the Cancer Center is conducive to innovative decision making.  
The significance of the problem was addressed by increasing the knowledge of 
nurses so they are better prepared to identify and care for patients with CIPN. One area of 
knowledge that was improved upon was autonomic nervous system dysfunction 
symptoms, such as hypotension, shortness of breath, impotence, and constipation. Not 
only did knowledge increase from pretest to posttest in these areas, nurses expressed to 
the project leader that they are more aware of symptoms of CIPN and are better able to 
identify patients who may have CIPN. It is reasonable to presume that the increase in 
nurses’ knowledge may improve care provided to vulnerable cancer patients. 
This project adds to the under-addressed, under-researched issue of CIPN by 
identifying a means to improve awareness and care for patients. With proper specialized 
education, oncology nurses can gain an increase in knowledge on CIPN and an increase 
in confidence to assess and identify patients at risk for, and with CIPN. Because of this 
project, there was an increase in knowledge and confidence about CIPN in nurses in the 
Cancer Center.  
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Limitations 
 Possibly the greatest limitation to interpretation of the results was attrition. There 
was a 20% response reduction from pretest to the first posttest and a 40% response 
reduction from the pretest to the second posttest. The reason for this was multifactorial. 
Around the time of the initiation of this project there were significant staffing changes in 
the clinic and infusion center. The clinic had been short staffed which may have 
increased nurse resistance to buy in to a project that did take time and effort. Shortly after 
project initiation the clinic had an influx of very novice nurses just out of nursing school. 
This may have made sustainability of patient assessments difficult because of the lack of 
knowledge. These new nurses were just honing basic nursing skills and may not have 
been ready to learn new, potentially more advanced skills. Perhaps specialty orientation 
should occur three to six months after employment. 
Attrition is a risk in any post-survey. Methods used to prevent a high attrition rate 
included distribution of contact information for the project leader with an open invitation 
to contact with questions at any time, regular face to face contact with managers and 
nursing staff, and email reminders to fill out and return the posttests. Additional methods 
to prevent attrition that could have been considered would include an incentive to turn in 
posttests and additional contact information gathered at the time of the initial test. 
Furthermore, offering an online testing option may have been more convenient and 
appealing to nurses and could be used in the future. Nursing resistance was not evident in 
the initial pretest and education; however, it likely contributed to attrition of posttests and 
sustainability of the patient assessment.  
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Discussions between the clinic and infusion center on where and when the 
assessment should take place occurred, as each area thought it would be best done in the 
other area. A clearer protocol enforced by nursing management with defined 
reassessment of the protocol, perhaps a month after initiation, may have improved 
acceptance and sustainability.  
Time could have been a factor in completing the posttests. While the tests were 
short, it still was an added task in what nurses perceived as an already busy day. Staffing 
issues contributed to the lack of nursing downtime. Assessment of the patient was felt to 
be time consuming, particularly by the clinic nurses. It would be expected to have slower 
assessment times and frustrations at initiation of a new process. Positive reinforcement 
was given; however, more time may still have been needed to allow for adjustment to the 
process. While initially perceived as beneficial to initiate patient assessments by nurses 
immediately following the education, perhaps the resistance to the process change caused 
resistance to the education posttests. Separating CIPN education and patient assessments 
with a period of time, perhaps one to two months, may also improve resistance. 
Additionally, a project dedicated to the evaluation of CIPN assessments would be 
warranted allowing a project leader more involvement and focus on this process alone. 
 Lack of concrete recommendations on nursing education, nursing knowledge 
assessment, and patient assessment posed a barrier. While there was an increase in 
knowledge, as evidenced by statistically significant increase in correct answers from 
pretest to posttests, the validity of the test is unknown. Face validity was performed; 
however, further evaluation should be done to show if the questions are adequate to test 
nursing knowledge. Lack of concrete recommendations on how patients should be 
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assessed continues to be a barrier because the clinic would like to improve patient 
assessments but were somewhat unsuccessful immediately following this project.   
Recommendations for Practice 
 Based on the increased knowledge level and confidence in assessment, it would 
be recommended to implement education on CIPN for all nursing staff. One 
recommendation extrapolated from this project would be to have education at regular 
intervals. While the Cancer Center does have educational sessions once or twice a month, 
which are an hour long and often very in depth topics, it was discussed that perhaps 
smaller topics could be educated on in a shorter format, perhaps a PowerPoint 
presentation emailed to all the nurses to be read at their convenience with an independent 
posttest for knowledge evaluation. CIPN, for example, could be discussed once or twice a 
year as a refresher. Staffing changes can also be addressed with this format. Just in the 
time of this project’s implementation, there were multiple new nurses who started in the 
Cancer Center. Continual rotation of important topics, such as CIPN, throughout the year 
may improve knowledge deficits and improve care for patients in this specialty 
population. This continual rotation of education can address research and EBP changes as 
well.   
Prior to project initiation, providers expressed a desire to better assess patients for 
CIPN. Little feedback was given on what exactly was desired content for the 
assessments. There was a perceived lack of provider acknowledgement of the information 
obtained by the nurses, which caused frustration on behalf of the nurses. For future 
modifications of the CIPN patient assessments, more information could be gathered from 
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the providers on what worked, what didn’t work, and recommendations for nursing 
practice change.  
Recommendations for Future Projects 
Recommendations for future projects include means of improving cancer patients’ 
symptoms and QoL, specifically in regards to CIPN. While research has made great gains 
in addressing common symptoms from cancer and chemotherapy such as nausea and 
neutropenia, more research needs to be done in the area of CIPN. More research needs to 
be done to determine the best format and content for nursing education on CIPN. More 
research is also needed to determine the most usable, efficient method for nurses to assess 
for CIPN in an outpatient clinic.  
Future research should be aimed at validating the best format and content for 
nursing education on CIPN. Further inquiry is also suggested with a larger sample size of 
nurses and a confidence and knowledge test that has been tested for validity. More 
research is also needed to determine the most usable, efficient method for nurses to assess 
for CIPN in an outpatient clinic. Additional EBP projects on CIPN are needed to improve 
the care and outcomes of cancer patients.  
Conclusion 
CIPN can be debilitating, decrease QoL, and possibly even decrease the life of 
cancer patients who have received neurotoxic chemotherapy (Stubblefield et al., 2009). 
Nurses are well suited to make a positive impact on the way we care for patients with or 
at risk for CIPN. Despite the fact that there is no gold standard for CIPN nursing 
education and patient assessments, and much more research needs to be done on this 
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topic, this EBP project successfully educated nurses and increased their confidence in 
CIPN. Further inquiry is suggested with a larger sample size and a confidence and 
knowledge test that has been tested for validity.  
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Appendix A 
NCCN Distress Thermometer for Patients 
 
Retrieved from 
http://www.nccn.org/patients/resources/life_with_cancer/pdf/nccn_distress_thermometer.pdf 
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Appendix B 
Nursing Education PowerPoint 
What is CIPN?
 Damage to axons, myelin sheaths, or cell bodies
 Adverse Effect of Neurotoxic Chemotherapy
 Peripheral Nervous System is more sensitive to 
neurotoxic chemotherapy
 Usually starts distally- toes, fingertips
 Stocking-glove distribution
 Axons may repair when chemotherapy stopped
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Appendix C 
Evidence Table 
Article 
# 
First Author, 
Date, & Title 
Evidence 
type 
Sample, 
Sample Size & 
Setting 
Study findings that help 
answer the EBP question 
Limitations Evidence 
level & 
Quality 
1 Binner, Ross, 
& Brownder, 
2011 
 
Chemotherap
y-Induced 
Peripheral 
Neuropathy: 
Assessment of 
Oncology 
Nurses’ 
Knowledge 
and Practice 
Cross-
sectional 
exploratory 
39 oncology 
nurses from 2 
hospital-based 
outpatient 
chemo clinics; 
convenience 
sample 
Nurses believe CIPN 
assessment is important and is 
a problem; Nurses are not 
confident in their CIPN 
assessment skills; Knowledge 
deficits exist for non-pharm 
management strategies, 
autonomic neuropathy as a 
form of PN (hypotension), med 
term for CIPN sensations; 15% 
of nurses received previous 
instruction on how to perform 
assessment for CIPN; barriers 
include limited proficiency, 
time, cumbersome 
documentation; 33% screen for 
baseline PN; practice 
integration is lacking 
Self-selected sample; 
survey structure may 
have led to prompts- 
not necessarily 
completely accurate; 
applicability to other 
practices 
Level IIIA-
B 
2 Tofthagen, 
Visovsky, & 
Hopgood 
(2013)  
Literature 
review, EBP 
Algorithm 
recommendati
NA An algorithm developed to be 
used by nurses in multiple care 
settings; researched and 
clinical expertise developed; 
Not research backed- 
validated 
Level VA 
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Chemotherap
y-Induced 
Peripheral 
Neuropathy: 
An Algorithm 
to Guide 
Nursing 
Management 
on list of nursing interventions; 
describes how to perform 
assessments 
3 Mann, 2008 
 
Neuropathic 
pain: could 
nurses 
become more 
involved? 
Literature 
review/editori
al 
NA Nurse assessment and 
management of neuropathic 
pain is a viable option in this 
under-addressed medical 
concern; personal contact time 
is essential in identifying 
symptoms early which in turn 
potentially initiates and 
effectively manages treatment; 
nurses have this time and 
ability; nurses can help with 
non-pharm interventions 
Some literature 
support- significant 
amount of opinion 
Level VB 
4 Mols, et al., 
2013 
 
Chemotherap
y-Induced 
Neuropathy 
and Its 
Association 
With Quality 
of Life 
Descriptive 
comparative 
and 
prevalence 
1643 patients 
diagnosed with 
colorectal 
cancer 
identified 
through a 
cancer registry; 
convenience 
sample 
Patients with multiple 
neuropathy symptoms report 
lower QOL; CRC patients 
continue to report neuropathy 
symptoms 
Limited data on 
previous use of the 
EORTC QLQ-
CIPN20; 
comorbidities were 
difficult to account 
for; no baseline 
assessment prior to 
treatment; self-report 
of PN- no clinical 
Level III B  
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Among 2- to 
11-Year 
Colorectal 
Cancer 
Survivors: 
Results From 
the 
Population-
Based 
PROFILES 
Registry 
 
assessment; chemo 
dosage not known; 
causal association 
between CIPN and 
HRQOL not 
determined; not 
randomized study 
5 Tofthagen, 
2010 
 
Patient 
Perceptions 
Associated 
With 
Chemotherap
y-Induced 
Peripheral 
Neuropathy 
Qualitative; 
purposive 
convenience 
sample 
14 cancer 
patients who 
have received 
certain chemos 
in an outpatient 
clinic setting 
Discusses importance of 
patient-reported symptoms; 
importance of subjective and 
objective measures; CIPN 
negatively affects QOL; proper 
management of CIPN is 
important for patient safety- 
falls; thorough and frequent 
exams by nurses can improve 
patient QOL 
Small sample size; 
demographics not 
necessarily 
generalizable; bias r/t 
researcher = provider; 
lapse of time from tx 
completion to study; 
no objective or 
systematic 
assessment 
Level IIIB 
6 Lavoie Smith, 
2103 
 
Current 
Methods for 
the 
Assessment 
and 
Literature 
review 
NA Oncology nurses are aware PN 
is an issue, but not sure what to 
do about it; TNS and 
FACT/GOG-Ntx; good table 
of measurement tools; 
“validated assessment tools 
should be administered … 
prior to each taxane 
 Level VA-B 
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Management 
of Taxane-
Related 
Neuropathy 
treatment”; “provides practical 
suggestions for how nurses can 
take the lead in improving 
TIPN measurement practices”; 
good discussion on what to 
look for/how to evaluate, good 
use of case examples 
7 R. Wickham 
2007 
 
Chemotherap
y-Induced 
Peripheral 
Neuropathy: 
A Review and 
Implications 
for Oncology 
Nursing 
Practice 
Literature 
review 
NA Good article for review of 
CIPN including 
pathophysiology; Good 
description of peripheral nerve 
pathophys and why they are 
sensitive to certain 
chemotherapies; PN are more 
sensitive than central nerves; 
need better patient education; 
incidence of CIPN is unknown, 
more common w/ vincristine, 
taxanes, and platinums; CIPN 
likely to increase r/t longer life 
expectancy and more 
neurotoxic agents; good tables 
with neurotoxic chemos and 
grading scales, and nursing 
care; online resources; 
objective finding of screening 
must include functional 
impairment; CIPN may be 
bothersome but tolerable if 
cure is intent, whereas 
palliative chemo may have 
 Level VA-B 
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lower threshold; 
comprehensive assessment 
impractical for nurses, can 
identify patients at risk  and 
perform brief assessments 
8 Paice, 2009 
 
Clinical 
challenges: 
Chemotherap
y-induced 
peripheral 
neuropathy 
Literature 
review 
NA Managing CIPN is 
challenging; will become more 
common with more 
chemotherapy agents and 
longer survival; prevalence is 
unknown because it is not well 
studied; no standardized 
assessment or staging system; 
self-report the most common 
method of evaluation, not 
systematic; table of validated 
tools;  
 Level VB 
9 Postma & 
Heimans, 
2000 
 
Grading of 
chemotherapy
-induced 
peripheral 
neuropathy 
Literature 
review 
NA Not an overly helpful article; 
lists some grading scales; 
recommends standardized 
grading scale plus QOL; 
limited indications for EP 
studies; assess during and after 
chemo administration 
Age- 2000 Level IVB-
C 
CIPN EDUCATION AND ASSESSMENT  66 
 
10 Visovsky, 
Collins, 
Abbott, 
Aschenbrenne
r, & Hart, 
2007 
 
Putting 
evidence into 
practice: 
Evidence-
based 
interventions 
for 
chemotherapy
-induced 
peripheral 
neuropathy 
Evidence-
based review 
NA Incidence unknown r/t no 
standardized measurement; 
concerning issue because of 
need for dose reductions, 
treatment delays, or 
termination of treatment; no 
meta-analyses found for 
prevention or treatment; no 
recommended/research 
supported nursing 
interventions for prevention or 
treatment; no pharmacologic or 
non-pharmacologic 
interventions were rigorously 
supported; need studies with 
more rigor, standardization and 
adequate sample size; only 
recommendations that can be 
made are for education and 
support 
 Level IV A 
11 
 
Kiser, Greer, 
Wilmoth,  
Dmochowski, 
& Naumann, 
2010 
 
Peripheral 
Neuropathy in 
Patients With 
Gynecologic 
Cancer 
Observational 
descriptive 
with 
retrospective 
review 
171gynecologic 
oncology 
patients who 
received 
chemotherapy, 
convenience 
sample  
No standardized grading of PN 
or self-reporting of PN exists; 
EP scores have little value as 
they do not correlate with 
patient subjective symptoms; 
having received neurotoxic 
chemo previously seems to 
decrease reporting of 
neuropathy in subsequent 
treatments; gaps in provider 
charting and grading; 
Retrospective 
analysis, convenience 
sample, low 
completion rate, gaps 
in data, no labeling 
on data as to order of 
treatment 
Level IIIB 
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Receiving 
Chemotherap
y: 
Patient 
Reports and 
Provider 
Assessments 
impossible to determine true 
prevalence of CIPN because of 
data gaps; Nurses should be 
leaders in identifying CIPN 
and its effects on QOL; 
oncology nurses must be 
knowledgeable about CIPN 
and educate patients; nurses 
play a crucial role in ensuring 
patients have good QOL and 
appropriate treatment 
12 Maxwell, 
2013 
 
Quality-of-
Life 
Consideration
s With 
Taxane-Based 
Therapy in 
Metastatic 
Breast 
Cancer: 
A Case 
Vignette 
Case vignette NA Infusion nurses are first line 
defense as they administer 
chemo; nurses don’t have the 
time to do proper CIPN 
assessments; initial and 
continued nursing assessments 
and education are important; 
teach patients to report 
symptoms; nurses are 
“frontline managers of 
supportive care” 
 Level V B 
13 Lavoie Smith, 
Beck & 
Cohen,  2008 
 
The Total 
Neuropathy 
Systematic 
review 
NA Nerve conduction studies are 
considered gold standard, yet 
they are expensive, time 
consuming, and do not 
correlate well with subjective 
reports; 3 challenges- nerve 
 Level IV B 
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Score: A Tool 
for Measuring 
Chemotherap
y-Induced 
Peripheral 
Neuropathy 
pain is not always reported 
with routine pain assessments; 
CIPN is difficult to describe; 
oncologists don’t see CIPN as 
being a big concern; 
appropriate tool has not been 
developed yet; TNS is most 
comprehensive; should be 
considered for use by oncology 
nurses; assessments should 
include patient distress r/t 
CIPN; no literature to support 
screening by nurses, but TNS 
could easily be taught to nurses 
to use; need more research 
regarding nurses ability to 
accurately assess 
14 Stubblefield 
et al., 2009 
 
NCCN Task 
Force Report: 
management 
of neuropathy 
in Cancer 
Task force 
report/guideli
ne 
NA Ideal resource for definitions 
and signs and symptoms; list 
of cancer related causes of PN; 
CIPN is the most widely 
reported PN in cancer patients; 
diagnostic features unique to 
CIPN; CIPN is recognized as 
an adverse event but not the 
focus of studies as response or 
survival is; multi-agent 
therapies make studying 
difficult; pre-existing 
conditions as a study 
limitation; evaluation based on 
 Level IVA 
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self-report rather than active 
probing; need better teaching 
on pain terms and associated 
conditions; “quality 
assessment and reporting 
leading to accurate diagnosis is 
a crucial step that must precede 
clinical decisions regarding 
treatment”; no gold standard 
for evaluation of CIPN; current 
assessments include clinical 
evaluation (grading systems), 
objective testing, and 
questionnaires; CIPN is 
subjective which makes 
evaluation more complex; poor 
correlation between subjective 
and objective data; patient 
tolerance and patient 
preference influence 
interventions; the task force 
strongly encourages active 
assessment at baseline and 
intermittently during therapy; 
recommends use of a 
neuropathic pain specific scale; 
education is necessary in 
interim while more studies are 
done on treatment 
15 Hershman et 
al., 2014 
Practice 
Guideline 
NA Overall, well written guideline; 
it is limited in that there is 
 Agree II  
score of 7 
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ASCO 
 
Prevention 
and 
management 
of 
chemotherapy 
induced 
peripheral 
neuropathy in 
survivors of 
adult cancers: 
American 
society of 
clinical 
oncology 
practice 
guideline 
limited reliable data; bottom 
line is there needs to be more 
high quality research done; no 
consistent or conclusive 
evidence that prevention or 
treatment strategies work; 
communication between 
provider and patient are 
important for identification and 
management; need discussion 
along with numeric scale 
16 Griffith et al., 
2014 
 
Evaluation of 
chemotherapy
-induced 
peripheral 
neuropathy 
using current 
perception 
threshold and 
clinical 
Prospective 
observational 
pilot study 
29 chemo-naïve 
cancer patients 
who will 
receive taxane 
or platinum 
chemo in an 
outpatient 
cancer center; 
convenience 
sample 
Patients were studied prior to 
chemo and with each cycle; 
used NCI-CTCAE v3.0; 
measured CPT, QST, and 
mechanical sensation of right 
great toe; measured grip 
strength of dominant hand and 
DTR of rightankle; subjective 
questionnaires- neuropathic 
pain scale, FACT/GOG-ntx; 
increased CPT readings may 
predict impending reduction in 
Relatively small 
sample size, subject 
heterogeneity, 
multiple examiners- 
different 
interpretations, need 
more robust measure 
of CIPN 
Level IIIA-
B 
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evaluations QOL; NCI-CTCAE score is 
associated with CPT 2000-  
impairment and hypoesthesias 
occur together; CPT 2000 is a 
feasible tool to use for 
screening CIPN patients 
17 Lavoie Smith,  
Cohen, Pett, 
& Beck 2011 
 
The Validity 
of Neuropathy 
and 
Neuropathic 
Pain 
Measures in 
Patients With 
Cancer 
Receiving 
Taxanes 
and Platinums 
Cross-
sectional 
117 cancer 
patients in 2 
outpatient 
cancer centers; 
convenience 
sample 
TNSr-SF and NPS-CIN took 5 
mins to complete; TNSr-SF 
was simpler to use than TNSr; 
reflexes should be measured 
but don’t need to be included 
in the TNS; the TNSr-SF used 
in combination 
with the NPS-CIN is preferred 
over the NCI-CTC; nurses 
should find the TNSr-SF and 
NPS-CIN the easiest of all 
measures to use within busy 
clinical settings; nurse-
physician collaboration will 
lead to better patient care and 
patient outcomes, detect subtle 
changes, more timely care 
Relatively small 
sample size; limited 
available research 
Level IIIB 
18 Griffith, 
Merkies, Hill, 
& Cornblath, 
2010 
 
Measures of 
chemotherapy
-induced 
Systematic 
review 
NA Systematic review of validity, 
reliability, and responsiveness 
of CIPN measures; best tool 
must have subjective and 
objective measures; must be 
easy to use and minimal cost; 
FACT/GOG-Tnx and TNS 
clinical version are most 
 Level IV A-
B 
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peripheral 
neuropathy: a 
systematic 
review of 
psychometric 
properties 
promising 
19 Cavaletti et 
al., 2010 
 
Chemotherap
y-Induced 
Peripheral 
Neurotoxicity 
assessment: 
A critical 
revision of the 
currently 
available tools 
Non-
systematic 
review 
NA Reviews several CIPN 
evaluation tools; existing 
scales are not satisfactory 
(rationale delineated with each 
scale review); providers 
underestimate and underreport 
CIPN severity; TNSc and a 
reliable QOL questionnaire 
(EORTC QLQ-CIPN20) and 
pain assessment are most 
effective until better screening 
is developed 
Non-systematic Level VB 
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Appendix D 
Pretest and Posttests 
1. How confident are you in your knowledge about chemotherapy-induced 
peripheral neuropathy (CIPN)? (Please circle a number) 
Very confident  Somewhat confident  Not confident at all 
 5  4  3  2  1 
2. How confident are you in your ability to perform an assessment for CIPN? 
Very confident  Somewhat confident  Not confident at all 
 5  4  3  2  1 
3. How important do you believe it is to assess for CIPN? 
Very important  Somewhat important  Not important at all 
 5  4  3  2  1 
4. How often are you assessing for CIPN? 
Every patient   Just patients at risk I don’t know how to assess 
CIPN 
 5  4  3  2  1 
5. What is the likelihood of performing a CIPN assessment on patients if 
implemented in the clinic? 
Very likely   Somewhat likely  Not likely at all 
 5  4  3  2  1 
6. CIPN can cause persistent pain. 
a. True 
b. False 
7. CIPN can decrease patient’s ability to perform ADLs. 
a. True 
b. False 
8. Which of the following are signs or symptoms of CIPN? (may choose multiple) 
a. Numbness or tingling 
b. Pain 
c. Constipation 
d. Temperature intolerance 
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9. Which of the following are signs or symptoms of CIPN? (may choose multiple) 
a. Hypotension 
b. Gait disturbance 
c. Shortness of breath 
d. Impotence  
10. Patients often use this/these terms to describe CIPN. (may choose multiple) 
a. I feel like I’m always wearing gloves 
b. I can’t feel the heel of my foot 
c. I can’t pick up my pills from the counter 
d. The pain is hard to describe 
11. When assessing for pain, which of the following descriptions may indicate CIPN? 
a. Sharp 
b. Dull 
c. Burning 
d. All of the above 
12. It is important to assess for proprioception. Why? 
a. This will indicate if a patient is safe to drink water 
b. Patients with good proprioception should have their blood pressure 
monitored closely 
c. Patients with poor proprioception may need to walk with a cane and 
remove throw rugs from the house 
d. Patients with proprioception have frequent diarrhea 
 
13. Which medication is NOT known for causing neuropathy? 
a. Rituxan  
b. Taxol 
c. Carboplatin 
d. Thalidomide 
14. Which of these assessment findings may indicate CIPN? 
a. Patient walks straight down the hallway without assistance 
b. Decreased reflexes 
c. Heart rate of 90, regular rhythm 
d. A negative Romberg test 
15. Which information is NOT important at baseline to determine CIPN risk? 
a. Alcohol use 
b. Charcot-Marie-Tooth disease 
c. Diabetes 
d. Acetaminophen use 
16. Which term is NOT associated with CIPN side effects? 
a. Allodynia 
b. Dysesthesia 
c. Hyperreflexia 
d. Paresthesia  
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17. Which vinca alkaloid is MOST likely to cause CIPN? 
a. Vinblastine 
b. Vincristine 
c. Vindestine 
d. Vinorelbine 
18. CIPN always improves after cessation of chemotherapy. 
a. True 
b. False 
19. If a patient has not experienced CIPN before the last dose of cisplatin, they will 
not experience CIPN. 
a. True 
b. False 
20. Which medication is most known to cause acute-transient CIPN? 
a. Cisplatin 
b. Thalidomide 
c. Oxaliplatin 
d. Docetaxel 
21. Which of the following treatments do NCCN and ASCO support for use in 
preventing CIPN? 
a. Vitamin E 
b. Calcium and magnesium infusion 
c. Alpha lipoic acid 
d. None of the above 
22. According to ASCO, which medication is most research supported for the 
treatment of CIPN? 
a. Nortriptyline 
b. Venlafaxine  
c. Gabapentin 
d. Topical baclofen 
23. Which non-medication treatment may have benefit for patients with CIPN? 
a. Physical therapy 
b. Acupuncture 
c. TENS therapy 
d. All of the above 
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Appendix E 
Demographics Form 
1. What is your age?________ 
2. What is your gender? 
a. Female 
b. Male 
3. What is your ethnicity 
a. White  
b. Hispanic or Latino 
c. Black or African American 
d. Native American or American Indian 
e. Asian or Pacific Islander 
f. Other  
4. What is your highest nursing education level? 
a. Certificate 
b. Associates 
c. Bachelors 
d. Masters or higher 
5. What is your FTE status? 
a. Full time 
b. Part time 
6. Which area do you primarily work in? 
a. Clinic 
b. Infusion 
7. How many years have you been a nurse? 
a. 0-2 
b. 3-5 
c. 6-8 
d. 9-11 
e. 12-14 
f. 15 or more 
8. How many years have you been an oncology nurse? 
a. 0-2 
b. 3-5 
c. 6-8 
d. 9-11 
e. 12-14 
f. 15 or more 
9. Which of the following certifications do you have? (May choose both) 
a. OCN 
b. Chemotherapy & biotherapy 
10. Have you ever had formal training on Chemotherapy induced peripheral 
neuropathy? 
a. Yes  
b. No  
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Appendix F 
FACT/GOG-Ntx 
Not 
at all 
A little 
bit 
Some
-what 
Quite 
a bit 
Very much 
I have numbness or tingling in my hands ................................  0 1 2 3 4 
I have numbness or tingling in my feet ...................................  0 1 2 3 4 
I feel discomfort in my hands ..................................................  0 1 2 3 4 
I feel discomfort in my feet .....................................................  0 1 2 3 4 
I have joint pain or muscle cramps ..........................................  0 1 2 3 4 
I feel weak all over ..................................................................  0 1 2 3 4 
I have trouble hearing ..............................................................  0 1 2 3 4 
I get a ringing or buzzing in my ears .......................................  0 1 2 3 4 
I have trouble buttoning buttons ..............................................  0 1 2 3 4 
I have trouble feeling the shape of small objects when 
they are in my hand .................................................................  
 
0
 
1 
 
2 
 
3 
 
4 
I have trouble walking .............................................................  0 1 2 3 4 
 
Retrieved from www.facit.org/literatureretrieve.aspx?ID=42405  
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Appendix G 
South Dakota State University Institutional Review Board Approval 
SDSU IRB 
Dec 29, 2014 
Kim, 
Thanks for the update.  I believe that they would likely rule this activity as “not human 
subjects research,” possibly exempt human subjects research. 
 I am going to rule the activity to be “not human subjects research.”  With this 
determination, no other involvement of the SDSU IRB is required on your part.  Please 
let me know the determination Sanford makes, to complete our records. 
  
Thanks! 
Norm      
 Norman O. Braaten, PhD, CPIA 
Research Compliance Coordinator 
South Dakota State University 
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Appendix H 
Sanford Institutional Review Board Approval 
 
 
